DnaJ heat shock protein family B member 9 is a novel biomarker for fibrillary GN

Journal of the American Society of Nephrology

Volumn 29, Issue 1, 2018, Pages 51-56

  Dasari, Surendra ^a   Alexander, Mariam P ^a   Vrana, Julie A ^a   Theis, Jason D ^a   Mills, John R ^a   Negron, Vivian ^a   Sethi, Sanjeev ^a   Dispenzieri, Angela ^a   Highsmith, Edward W ^a   Nasr, Samih H ^a   Kurtin, Paul J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNAJ HEAT SHOCK PROTEIN FAMILY B MEMBER 9; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN; PROTEIN DNAJ; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CHAPERONE; DNAJB9 PROTEIN, HUMAN; HEAT SHOCK PROTEIN 40; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; MEMBRANE PROTEIN; PROTEOME;

AMINO ACID SEQUENCE; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; FIBRILLARY GLOMERULONEPHRITIS; GENE OVEREXPRESSION; GLOMERULONEPHRITIS; HUMAN; HUMAN TISSUE; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; PRIORITY JOURNAL; PROTEOMICS; SANGER SEQUENCING; SENSITIVITY AND SPECIFICITY; BIOPSY; CASE CONTROL STUDY; GENETICS; GLOMERULUS; METABOLISM; PATHOLOGY; ULTRASTRUCTURE;

BIOMARKERS; BIOPSY; CASE-CONTROL STUDIES; GLOMERULONEPHRITIS; HSP40 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN GAMMA-CHAINS; KIDNEY GLOMERULUS; MEMBRANE PROTEINS; MOLECULAR CHAPERONES; PROTEOME; SENSITIVITY AND SPECIFICITY;

EID: 85040101353     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2017030306     Document Type: Article

References (20)

1. Fogo A, Qureshi N, Horn RG: Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy. Am J Kidney Dis 22: 367–377, 1993
2. Rosenstock JL, Markowitz GS, Valeri AM, Sacchi G, Appel GB, D’Agati VD: Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. Kidney Int 63: 1450–1461, 2003
3. Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, Leung N, Fervenza FC: Fibrillary glomerulonephritis: A report of 66 cases from a single institution. Clin J Am Soc Nephrol 6: 775–784, 2011
4. Iskandar SS, Falk RJ, Jennette JC: Clinical and pathologic features of fibrillary glomerulonephritis. Kidney Int 42: 1401–1407, 1992
5. Markowitz GS, Cheng JT, Colvin RB, Trebbin WM, D’Agati VD: Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol 9: 2244–2252, 1998
6. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A: Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 114: 4957–4959, 2009
7. Theis JD, Dasari S, Vrana JA, Kurtin PJ, Dogan A: Shotgun-proteomics-based clinical testing for diagnosis and classification of amyloidosis J Mass S Ectrom 48:1067–1077 2013
8. Li M, Gray W, Zhang H, Chung CH, Billheimer D, Yarbrough WG, Liebler DC, Shyr Y, Slebos RJ: Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling. J Proteome Res 9: 4295–4305, 2010
9. Alpers CE, Kowalewska J: Fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol 19: 34–37, 2008
10. Bridoux F, Hugue V, Coldefy O, Goujon JM, Bauwens M, Sechet A, Preud’Homme JL, Touchard G: Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. Kidney Int 62: 1764–1775, 2002
11. Vrana JA, Theis JD, Dasari S, Mereuta OM, Dispenzieri A, Zeldenrust SR, Gertz MA, Kurtin PJ, Grogg KL, Dogan A: Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haemato-logica 99: 1239–1247, 2014
12. Chan TM, Chan KW: Fibrillary glomerulone-phritisinsiblings.Am J Kidney Dis 31:E4,1998
13. Ying T, Hill P, Desmond M, Agar J, Mallett A: Fibrillary glomerulonephritis: An apparent familial form? Nephrology (Carlton) 20: 506–509, 2015
14. Hogan J, Restivo M, Canetta PA, Herlitz LC, Radhakrishnan J, Appel GB, Bomback AS: Rituximab treatment for fibrillary glomerulonephritis. Nephrol Dial Transplant 29: 1925–1931, 2014
15. Javaugue V, Karras A, Glowacki F, McGregor B, Lacombe C, Goujon JM, Ragot S, Aucouturier P, Touchard G, Bridoux F: Long-term kidney disease outcomes in fibrillary glomerulonephritis: A case series of 27 patients. Am J Kidney Dis 62: 679–690, 2013
16. Kalbermatter SA, Marone C, Casartelli D, Hausberg M, Banfi G, Mihatsch M, Dickenmann M: Outcome of fibrillary glomerulonephritis. Swiss Med Wkly 142: w13578, 2012
17. Lee HJ, Kim JM, Kim KH, Heo JI, Kwak SJ, Han JA: Genotoxic stress/p53-induced DNAJB9 inhibits the pro-apoptotic function of p53. Cell Death Differ 22: 86–95, 2015
18. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P: Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 21: 221–224, 2014
19. Liu H, Sadygov RG, Yates JR 3rd: A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 76: 4193–4201, 2004
20. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL,; ACMG Laboratory Quality Assurance Committee: Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 17: 405–424, 2015